Growth Hormone Stack

Growth hormone research has a well-worn observation: the pituitary releases far more GH when two independent signals arrive together than when either arrives alone. The Growth Hormone Stack builds directly on that insight — pairing CJC-1295, a GHRH analogue, with Ipamorelin, a selective ghrelin-receptor agonist, so both receptor systems fire in the same window.

If you have wondered why GH secretion fades with age even though the pituitary still works, this pairing is the research answer taking shape: not replacing the hormone, but pressing both of its natural release buttons at once. Studies suggest the combined signal produces substantially greater GH release than either peptide alone [PMID: 9758556] — with minimal cortisol and prolactin spillover, thanks to ipamorelin's selectivity.

Ahead: how each receptor pathway works, why the dual-signal model produces synergy, and where the evidence stops short. Both compounds remain research peptides studied mainly in preclinical models and limited human pharmacokinetic work — a boundary this page keeps visible throughout.

CJC-1295 — also known as Modified GRF 1-29 — is a truncated, stabilized analogue of GHRH. Research suggests it binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile GH secretion and downstream IGF-1 production [PMID: 16352683]. The no-DAC version matters here: unlike the original long-acting form, its shorter half-life mimics natural GHRH pulses rather than flattening them into sustained elevation — a distinction researchers treat as essential for studying physiological rhythms.

Ipamorelin arrives through a separate door entirely. As a selective GHSR-1a agonist, it triggers GH release via the ghrelin receptor pathway, independent of the GHRH receptor [PMID: 9758556]. Two entry points converging on one cell type is the core rationale: studies suggest the paired stimulus produces a larger GH pulse than either compound generates alone [PMID: 9758556].

Ipamorelin's selectivity deserves its own moment. Earlier secretagogues such as GHRP-2 and GHRP-6 stimulated cortisol and prolactin alongside GH, muddying research interpretations. Ipamorelin appears to spare both hormones at standard doses [PMID: 9758556] — which is why it became the default ghrelin-side partner in combination research.

Endocrinology summarizes the model as GHRH + GHRP synergy: one analogue amplifies pulse amplitude through pituitary sensitization, the other adds a parallel ghrelin-axis stimulus. No human trial has tested this exact pairing — which leaves the well-established physiology of the GH axis carrying the argument, for now.

Both peptides go under the skin, and their timing relative to each other is the active design question. The prevailing idea is straightforward: co-administer both within a short window so the two receptor systems activate concurrently, maximizing the synergistic pulse. Natural GH axis research supports the principle — GHRH and ghrelin signals are strongest when delivered together [PMID: 9758556].

Anecdotal research literature most often references Ipamorelin at 200–300 mcg per injection, one to three times daily, anchored around sleep onset, fasting, or pre-exercise windows. CJC-1295 no-DAC typically appears at 100–200 mcg, co-administered in the same window [PMID: 16352683]. Its roughly 30-minute half-life suits pulsatile use; the DAC version's multi-day action does not.

Protocols described in the literature typically run 8–12 weeks — the span over which downstream IGF-1 and body composition endpoints become observable in preclinical models.

Because secretagogues engage the endocrine axis, researchers emphasize baseline measurements and washout periods before interpreting results. No human safety profile exists for the combination — worth remembering as the questions below dig into what this pairing raises.